68 / 69
68
hematopoietic cell transplantation for chronic myeloid
leukemia. Blood 2008;112:3500-7.
97.
Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner
JE, et al. Imatinib use either pre- or post-allogeneic
hematopoietic cell transplantation (allo-HCT) does not
increase cardiac toxicity in chronic myelogenous leukemia
patients. Bone Marrow Transplant 2009;44:169-74.
98.
Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, et al.
Imatinib combined with myeloablative allogeneic
hematopoietic stem cell transplantation for advanced
phases of chronic myeloid leukemia. Leuk Res
2011;35:1307-11.
99.
Jiang Q, Xu L, Liu D, Liu K, Chen S, Jiang B, et al. Imatinib
mesylate versus allogeneic hematopoietic stem cell
transplantation for patients with chronic myelogenous
leukemia
in
the
accelerated
phase.
Blood.
2011;117(11):3032-3040.
100.
Boehm A, Walcherberger B, Sperr WR, Wöhrer S,
Dieckmann K, Rosenmayr A, et al. Improved outcome in
patients with chronic myelogenous leukemia after
allogeneic hematopoietic stem cell transplantation over
the past 25 years: a single-center experience. Biol Blood
Marrow Transplant 2011;17:133-40.
101.
Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R,
Castagnetti F, et al. Second-generation tyrosine kinase
inhibitors before allogeneic stem cell transplantation in
patients with chronic myeloid leukemia resistant to
imatinib. Leuk Res 2010;34:143-7.
102.
Millot F,Baruchel A,
Guilhot J,
Petit A, Leblanc T, Bertrand Y,
et al. Imatinib is effective in children with
previously untreated chronic myelogenous leukemia in
early chronic phase: results of the French national phase
IV trial.
J Clin Oncol. 2011;29:2827-32.